Skip to content
value.today
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc.

Total raised
$412 M
1 round on record
Latest round
$412 M
Apr 2018
First round on record
Apr 2018
Today
Went public
See the company page

Allogene Therapeutics, Inc. is listed today as Allogene Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Allogene Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2018$412 MNo. 1$250 million to $1 billion

Allogene Therapeutics, Inc.: Raise no. 1, Apr 2018

Investors in this round

23 investors had bought by the notice of Apr 19, 2018: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Allogene Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$412 M of $412 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David M. Tanen · Executive Officer
  • Joshua A. Kazam · Executive Officer, Director
  • Arie M. Belldegrun · Director
  • David M. Bonderman · Director
  • David M. Chang · Director
  • Franz M. Humer · Director
  • John M. Deyoung · Director
  • Owen M. Witte · Director
  • Robert M. Abraham · Director
  • Todd M. Sisitsky · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The consideration for $111,770,405 of the total offering amount was non-cash consideration, and the consideration for $150,000,002 of the total offering amount was capital commitments.”

Signed by David M. Tanen, Secretary. Source: SEC Form D, newest notice filed Apr 19, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Allogene Therapeutics, Inc., its revenue in fiscal 2024 came from these business segments: Reportable $20,000 (100%).

    Annual report (SEC XBRL) · Dec 2024

  • Allogene Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2018).

    SEC Form D · Apr 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2018

Products and services#

No products or services of Allogene Therapeutics, Inc. are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in Allogene Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Franz B. HumerPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2018)SEC Form 3
Joshua A. KazamPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2018)SEC Form 3
Owen N. WittePersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2018)SEC Form 3
Pfizer IncFund or asset managernot statednot statedHeld Series A-1 preferred stock, 10% owner (Form 3, 2018)SEC Form 3
TPG Group Holdings (SBS) Advisors, Inc.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 23 investors.

Largest shareholders today

Institutions holding Allogene Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Allogene Therapeutics, Inc.
NameRoleNamed in
David M. TanenExecutive officerApr 2018
Joshua A. KazamExecutive officerApr 2018
Arie M. BelldegrunDirectorApr 2018
David M. BondermanDirectorApr 2018
David M. ChangDirectorApr 2018
Franz M. HumerDirectorApr 2018
John M. DeyoungDirectorApr 2018
Joshua A. KazamDirectorApr 2018
Owen M. WitteDirectorApr 2018
Robert M. AbrahamDirectorApr 2018
Todd M. SisitskyDirectorApr 2018

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.